Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women
- PMID: 28304400
- DOI: 10.1038/modpathol.2017.16
Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women
Abstract
The aim of this study was to evaluate the clinical utility of p16/Ki-67 dual staining, for the identification of CIN in high-risk HPV-positive women from a non-responder screening cohort. P16/Ki-67 dual staining, Pap cytology, and HPV16/18 genotyping were performed on physician-taken liquid-based samples from 495 women who tested high-risk HPV positive on self-sampled material (PROHTECT-3B study). Different triage strategies involving p16/Ki-67 dual staining were evaluated for sensitivity, specificity, and predictive value for ≥CIN2 and ≥CIN3, and compared to Pap cytology with a threshold of atypical cells of undetermined significance. Centrally revised histology or an adjusted endpoint with combined high-risk HPV negative and cytology negative follow-up at 6 months was used as gold standard. Pap cytology (threshold atypical cells of undetermined significance) triage of high-risk HPV-positive samples showed a sensitivity of 93% (95% confidence interval: 85-98) with a specificity of 49% (95% confidence interval: 41-56) for ≥CIN3. Three triage strategies with p16/Ki-67 showed a significantly increased specificity with similar sensitivity. P16/Ki-67 triage of all high-risk HPV-positive samples had a sensitivity of 92% (95% confidence interval: 84-97) and a specificity of 61% (95% confidence interval: 54-69) for ≥CIN3. Applying p16/Ki-67 triage to only high-risk HPV-positive women with low-grade Pap cytology showed a similar sensitivity of 92% (95% confidence interval: 84-97), with a specificity for ≥CIN3 of 64% (95% confidence interval: 56-71). For high-risk HPV-positive women with low-grade and normal Pap cytology, triage with p16/Ki-67 showed a sensitivity of 96% (95% confidence interval: 89-99), and a specificity of 58% (95% confidence interval: 50-65). HPV16/18 genotyping combined with Pap cytology showed a sensitivity and specificity for ≥CIN3 similar to Pap cytology with an atypical cells of undetermined significance threshold. Because the quality of Pap cytology worldwide varies, and differences in sensitivity and specificity are limited between the three selected strategies, p16/Ki-67 triage of all high-risk HPV-positive samples would be the most reliable strategy in triage of high-risk HPV-positive women with an increased specificity and similar sensitivity compared with Pap cytology triage.
Similar articles
-
p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population.Mod Pathol. 2016 Aug;29(8):870-8. doi: 10.1038/modpathol.2016.80. Epub 2016 May 6. Mod Pathol. 2016. PMID: 27150161
-
Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.Int J Cancer. 2015 May 15;136(10):2361-8. doi: 10.1002/ijc.29290. Epub 2014 Nov 6. Int J Cancer. 2015. PMID: 25345358
-
Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.Gynecol Oncol. 2011 Jun 1;121(3):505-9. doi: 10.1016/j.ygyno.2011.02.033. Epub 2011 Mar 21. Gynecol Oncol. 2011. PMID: 21420158
-
Management of high-risk HPV-positive women for detection of cervical (pre)cancer.Expert Rev Mol Diagn. 2016 Sep;16(9):961-74. doi: 10.1080/14737159.2016.1217157. Epub 2016 Aug 5. Expert Rev Mol Diagn. 2016. PMID: 27459506 Review.
-
p16INK4a/Ki67 Dual-Staining Immunocytochemistry to Refer Women Infected by High-Risk Human Papillomavirus for Colposcopy.Acta Cytol. 2025;69(1):16-25. doi: 10.1159/000542504. Epub 2025 Jan 17. Acta Cytol. 2025. PMID: 39827844 Review.
Cited by
-
Dual staining for p16/Ki67 is a more specific test than cytology for triage of HPV-positive women.Virchows Arch. 2018 Nov;473(5):599-606. doi: 10.1007/s00428-018-2432-z. Epub 2018 Aug 9. Virchows Arch. 2018. PMID: 30094492
-
Cervical Cancer Screening Postpandemic: Self-Sampling Opportunities to Accelerate the Elimination of Cervical Cancer.Int J Womens Health. 2021 Sep 18;13:841-859. doi: 10.2147/IJWH.S288376. eCollection 2021. Int J Womens Health. 2021. PMID: 34566436 Free PMC article. Review.
-
Adjunctive use of p16 immunohistochemistry for optimizing management of CIN lesions in a high-risk human papillomavirus-positive population.Acta Obstet Gynecol Scand. 2022 Nov;101(11):1328-1336. doi: 10.1111/aogs.14459. Epub 2022 Sep 30. Acta Obstet Gynecol Scand. 2022. PMID: 36177908 Free PMC article.
-
Triage Strategies for Non-16/Non-18 HPV-Positive Women in Primary HPV-Based Cervical Cancer Screening: p16/Ki67 Dual Stain vs. Cytology.Cancers (Basel). 2023 Oct 21;15(20):5095. doi: 10.3390/cancers15205095. Cancers (Basel). 2023. PMID: 37894462 Free PMC article.
-
Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review.Infect Agent Cancer. 2020 Nov 16;15(1):68. doi: 10.1186/s13027-020-00335-2. Infect Agent Cancer. 2020. PMID: 33292364 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous